# Tubulin polymerization-IN-34

**Cat. No.:** HY-151395

**Molecular Formula:** $C_{31}H_{35}N_3O_6$

**Molecular Weight:** 545.63

**Target:** Microtubule/Tubulin

**Pathway:** Cell Cycle/DNA Damage; Cytoskeleton

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Tubulin polymerization-IN-34 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line[1]. |
| **$IC_{50}$ & Target** | [1,2]oxazoloisoindoles tubulin polymerization[1] |
| **In Vitro** | Tubulin polymerization-IN-34 (compound 17i) (10 nM-100 μM; 72 h) has antiproliferative activity against 9 NCI subpanels (leukemia, non-small-cell lung, colon, central nervous system, melanoma, ovarian, renal, prostate, breast) with $GI_{50}$s ranging from 0.25 μM to 6.84 μM, and a mean graph_mid point (MG_MID) values of 0.95 μM[1].<br>Tubulin polymerization-IN-34 (0.15-10 μM; 72 h) shows potent growth inhibitory effects on different lymphoma lines, and demonstrates high selectivity against the VL51 cell line (Marginal zone lymphoma, $IC_{50}$=0.2 μM)[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

Cell Viability Assay[1]

| | |
|---|---|
| Cell Line: | Marginal zone lymphoma, mantle cell lymphoma, activated B-cell like diffuse large B cell lymphoma, germinal center B-cell-like diffuse large B cell lymphoma cells |
| Concentration: | 0.15-10 μM |
| Incubation Time: | 72 h |
| Result: | Inhibited different lymphomas, with $IC_{50}$s of 0.2 μM (Marginal zone lymphoma); 0.5 μM (mantle cell lymphoma); 0.5 μM (activated B-cell like diffuse large B cell lymphoma); 0.5 μM (germinal center B-cell-like diffuse large B cell lymphoma), respectively. |

## REFERENCES

[1]. Marilia Barreca, et al. Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas, European Journal of Medicinal Chemistry. 2022, 114744, ISSN 0223-5234.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA